Status:
RECRUITING
68Ga-DOTATATE PET/CT for the Diagnosis of Soft Tissue Sarcomas
Lead Sponsor:
Ohio State University Comprehensive Cancer Center
Conditions:
Soft Tissue Sarcoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This trial studies how well 68Ga-DOTATATE digital PET/CT work in diagnosing soft tissue sarcoma. 68Ga-DOTATATE is a radiotracer that may improve image quality of PET imaging. PET is an established ima...
Detailed Description
PRIMARY OBJECTIVE: I. To assess the feasibility and capability of gallium Ga 68-HA-DOTA-TATE (68Ga-DOTATATE) digital positron emission tomography (dPET)/ computed tomography (CT) imaging for soft tis...
Eligibility Criteria
Inclusion
- Patients \>= 18 years of age
- Patients diagnosed with any stage of soft tissue sarcomas candidates for systemic therapies
- Patients with one standard of care PET/CT scan up to 30 days before enrollment at the Ohio State University facilities.
Exclusion
- Hypersensitivity to somatostatin or similar peptides
- Somatostatin long-acting analog in the past 6 months
- Patients who are pregnant or lactating
- Patients who are currently incarcerated
- Patients with acute infections
- Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)
- Patients exceeding the weight limitations of the scanner or are not able to enter the bore of the dPET/CT scanner due to body mass index (BMI)
Key Trial Info
Start Date :
September 30 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06500065
Start Date
September 30 2024
End Date
December 31 2025
Last Update
November 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States, 43210